Ibrutinib versus bendamustine plus rituximab for first-line treatment of 65 or older patients with untreated chronic lymphocytic leukemia without del(17p)/TP53 mutation in China: a lifetime economic research study

被引：0
|
作者：
Yuan Hong
Xichuang Chen
Yuanquan Hong
Xingfang Xiao
Yan Wang
Xiaohong You
Jingyi Mi
Tao Zhou
Panpan Zheng
Zhihu Huang
机构：
[1] Affiliated Children’s Hospital of Jiangnan University (Wuxi Children’s Hospital),Department of Pharmacy
[2] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),Department of Pharmacy
[3] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),Department of Sports Medicine
[4] Department of Pharmacy,Department of Oncology
[5] Wuxi Ninth People’s Hospital Affiliated to Soochow University (Wuxi Orthopedic Hospital),undefined
来源：
BMC Health Services Research | / 23卷
关键词：
Chronic lymphocytic leukemia; Cost effectiveness; Ibrutinib; Bendamustine; Rituximab; Quality adjusted life-year;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 33 条
  • [31] Broad Superiority of Zanubrutinib (Zanu) Over Bendamustine plus Rituximab (BR) Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive (TN) Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) without del(17p)
    Ramakrishnan, Vanitha
    Xu, Linlin
    Paik, Jason C.
    Marimpietri, Carol
    Shen, Eric
    Dong, Xiaoxi
    Li, Jessica
    Agathangelidis, Andreas
    Tian, Tian
    Cohen, Aileen Cleary
    Robak, Tadeusz
    Tam, Constantine S.
    Ghia, Paolo
    Rawstron, Andrew
    Brown, Jennifer R.
    BLOOD, 2023, 142
  • [32] 6-Year Time to Next Treatment (TTNT) Extrapolation Curve for GLOW Study: First-Line Ibrutinib Plus Venetoclax (I plus V) Offers Long Treatment-Free Period for Older Adult/Unfit Patients With Chronic Lymphocytic Leukemia (CLL)
    Ossorio Prendes, Santiago
    Gimeno, Vicente
    Hernandez Rivas, Jose Angel
    Lopez Jimenez, Francisco Javier
    Diels, Joris
    Schioppa, Claudio
    Alfayate Lobo, Ana
    Dominguez-Lubillo, Teresa
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S355 - S356
  • [33] PREDICTIVE POWER ON PROGRESSION FREE SURVIVAL (PFS) OF TP53 MUTATIONAL STATUS BY NEXT GENERATION SEQUENCING (NGS) ION TORRENT AMPLISEQ-TM TECHNOLOGY IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS TREATED WITH THE COMBINATION SCHEDULE OF BENDAMUSTINE AND RITUXIMAB (BR) AS FIRST-LINE - SCREENING OF 39 CASES
    Gentile, M.
    De Stefano, L.
    Bossio, S.
    Uccello, G.
    Vigna, E.
    Palummo, A.
    Caruso, N.
    Iaquinta, G.
    Storino, F.
    Neri, A.
    Barbieri, M.
    Favoino, C.
    Lionetti, M.
    Cutrona, G.
    Fais, F.
    Tassone, P. F.
    Recchia, A. G.
    Morabito, F.
    HAEMATOLOGICA, 2016, 101 : S80 - S81
1234